![Robert Emanuele](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Emanuele
Direktor/Vorstandsmitglied bei
ARTELO BIOSCIENCES, INC.
Vermögen: 53 $ am 30.06.2026
Profil
Robert Martin Emanuele was the founder of Synthrx, Inc., founded in 2008, where the title held was President & Chief Executive Officer from 2008 to 2010.
Dr. Emanuele is also the founder of Visgenx, Inc...
Current positions include President & Chief Executive Officer at Liferaft Biosciences, Inc., and Independent Director at Artelo Biosciences, Inc. since 2017.
Former positions include Principal at EIDP, Inc.; Vice President-Research & Development at LadRx Corp.
from 1988 to 2002; Vice President-Pharmaceutical Strategy at DaVita, Inc. from 2010 to 2011; Senior Vice President-Business Development at Kémia, Inc. from 2006 to 2008; Chief Business Officer at Virobay, Inc.; Clinical Research Scientist at Dupont Critical Care, Inc.; VP-Corporate Development & Portfolio Management at Avanir Pharmaceuticals, Inc. from 2002 to 2006; Senior Vice President-Development at Mast Therapeutics, Inc. from 2011 to 2016; and Senior Vice President-Development at Savara, Inc. from 2011 to 2016.
Education includes undergraduate studies at Colorado State University, an MBA from The University of Colorado, and a doctorate from Stritch School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 17.07.2026 | 47 ( 0 % ) | 53 $ | 30.06.2026 |
Aktive Positionen von Robert Emanuele
| Unternehmen | Position | Beginn |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 20.09.2017 |
Liferaft Biosciences, Inc. ,
 Liferaft Biosciences, Inc. , MiscellaneousMiscellaneous Operates as a non-classified establishment | Vorstandsvorsitzender | - |
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Develops therapeutics to protect against the loss of sight from retinal disorders | Gründer | - |
Ehemalige bekannte Positionen von Robert Emanuele
| Unternehmen | Position | Ende |
|---|---|---|
| SAVARA INC. | Corporate Officer/Principal | 28.10.2016 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies for serious or life-threatening diseases with significant unmet needs | Corporate Officer/Principal | 01.10.2016 |
| DAVITA INC. | Corporate Officer/Principal | 01.04.2011 |
Synthrx, Inc.
 Synthrx, Inc. Miscellaneous Commercial ServicesCommercial Services Develops a purified form of a rheologic and antithrombotic agent | Vorstandsvorsitzender | 01.04.2010 |
Kémia, Inc.
 Kémia, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel small molecule therapeutics | Corporate Officer/Principal | 01.05.2008 |
Ausbildung von Robert Emanuele
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
46
Beziehungen ersten Grades
16
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 16 |
|---|---|
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries Manufactures and sells seed & crop protection products | Process Industries |
LadRx Corp.
 LadRx Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical research and development oncology company | Health Technology |
DaVita, Inc.
 DaVita, Inc. Medical/Nursing ServicesHealth Services Provides integrated dialysis services for patients suffering from chronic kidney failure | Health Services |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products for the treatment of nervous system disorder | Health Technology |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies for serious or life-threatening diseases with significant unmet needs | Health Technology |
Kémia, Inc.
Kémia, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel small molecule therapeutics | Health Technology |
Virobay, Inc.
 Virobay, Inc. Pharmaceuticals: MajorHealth Technology Develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases | Health Technology |
Artelo Biosciences, Inc.
 Artelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops endocannabinoid system modulating therapeutics | Health Technology |
Colorado State University
 Colorado State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Colorado
 The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dupont Critical Care, Inc. | |
Synthrx, Inc.
Synthrx, Inc. Miscellaneous Commercial ServicesCommercial Services Develops a purified form of a rheologic and antithrombotic agent | Commercial Services |
Stritch School of Medicine
 Stritch School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Savara, Inc.
 Savara, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals to treat respiratory diseases | Health Technology |
Liferaft Biosciences, Inc. ,
Liferaft Biosciences, Inc. , MiscellaneousMiscellaneous Operates as a non-classified establishment | Miscellaneous |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Develops therapeutics to protect against the loss of sight from retinal disorders | Health Technology |
